CG Oncology, Inc. (CGON)
57.30
+2.38
(+4.33%)
USD |
NASDAQ |
Jun 11, 10:56
CG Oncology EPS Diluted (Quarterly) : -0.7123 for March 31, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | -0.7123 |
| December 31, 2025 | -0.5157 |
| September 30, 2025 | -0.5709 |
| June 30, 2025 | -0.5435 |
| March 31, 2025 | -0.4522 |
| December 31, 2024 | -0.4175 |
| September 30, 2024 | -0.3021 |
| Date | Value |
|---|---|
| June 30, 2024 | -0.2836 |
| March 31, 2024 | -0.3598 |
| December 31, 2023 | -0.3309 |
| September 30, 2023 | -0.2694 |
| June 30, 2023 | -0.2309 |
| March 31, 2023 | -0.1861 |
| December 31, 2022 | -0.1825 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Cogent Biosciences, Inc. | -0.60 |
| Vera Therapeutics, Inc. | -1.693 |
| Arrowhead Pharmaceuticals, Inc. | -0.932 |
| Oncolytics Biotech, Inc. | -0.0823 |
| Sangamo Therapeutics, Inc. | -0.0796 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -60.20M |
| Revenue (Quarterly) | 1.083M |
| Total Expenses (Quarterly) | 61.28M |
| Enterprise Value | 3.765B |
| Gross Profit Margin (Quarterly) | -177.3% |
| Profit Margin (Quarterly) | -5.56K% |
| Earnings Yield | -4.09% |
| Normalized Earnings Yield | -4.088 |